22. Moyamoya disease
11 clinical trials,   18 drugs   (DrugBank: 11 drugs),   28 drug target genes,   43 drug target pathways

Searched query = "Moyamoya disease", "Occlusive disease in circle of Willis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04205578
(ClinicalTrials.gov)
January 202018/12/2019NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular EventsA Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization SurgeryMoyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic AttackDrug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solutionyuanli ZhaoPeking University International HospitalNot yet recruiting18 Years60 YearsAll450Phase 3China
2NCT03882060
(ClinicalTrials.gov)
April 8, 201912/3/2019Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya PatientsThe Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled TrialMoyamoya Disease;Pediatrics;Cerebrovascular DisordersDrug: erythropoietin;Drug: Normal salineSeoul National University HospitalNULLRecruitingN/A18 YearsAll82N/AKorea, Republic of